Trial reportBlood2017
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.
Trial report in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 2 syntheses or guidelines pooled it, 336 citations in OpenAlex.
- American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis.Blood advances · 2026Guideline
- Global epidemiology of amyloid light-chain amyloidosis.Orphanet journal of rare diseases · 2022Pooled it
- Preclinical and preliminary clinical evaluation of [European journal of nuclear medicine and molecular imaging · 2026Trial
- Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis.Blood neoplasia · 2025Trial
- Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.Annals of hematology · 2023Trial
- Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis.Blood advances · 2022Trial
- A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.Leukemia · 2022Trial
- Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study.Blood cancer journal · 2021Trial
- Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis.American journal of hematology · 2021Trial
- Trial
- The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis.Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2020Trial
- A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis.American journal of hematology · 2026Article
- Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020.Bone marrow transplantation · 2026Article
- When AL amyloidosis meets the liver: integrating clinical insight and current understanding.Annals of hematology · 2026Review
- Rare case of young cardiac amyloidosis: difficult diagnostic pathway in routine clinical care.European heart journal. Case reports · 2026Article
- Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 Patients.JACC. CardioOncology · 2026Article
- Concurrence of renal amyloidosis and membranous nephropathy: a case series and literature review.BMC nephrology · 2026Review
- Outcomes of patients with systemic light chain amyloidosis treated with DVD front-line therapy.Cardio-oncology (London, England) · 2026Article
- Patient with AL amyloidosis with recurrent syncope as the first symptom: case report and literature review.Frontiers in oncology · 2026Article
- Closing the diagnostic gap in transthyretin cardiac amyloidosis: red flags, modern imaging, and emerging therapies.Frontiers in cardiovascular medicine · 2026Review
84 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors at 1 institution in 1 country.
Funding
Abstract
In light of major advances in immunoglobulin light chain (AL) amyloidosis, we evaluated the trends in presentation, management, and outcome among 1551 newly diagnosed AL amyloidosis patients seen in our institution from 2000 to 2014. As compared with the 2 intervals 2000-2004 and 2005-2009, patients diagnosed in 2010-2014 were less likely to have >2 involved organs. Utilization of autologous stem cell transplant (ASCT) was similar across all periods, about one-third of patients, but there was an increase in the use of pre-ASCT bortezomib induction and of unattenuated melphalan conditioning in 2010-2014 compared with earlier periods. Non-ASCT first-line regimen changed with 65% of patients in 2010-2014 received bortezomib-based therapy, 79% of patients in 2005-2009 received melphalan-dexamethasone, and 64% of patients in 2000-2004 received melphalan-prednisone. The rate of better than very good partial response (VGPR) was higher in more recent periods (66% vs 58% vs 51%;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.